VENTASWITCH, Examination of Ventavis® (Iloprost) Inhalation Behavior Using the I-Neb® AAD® System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
Phase of Trial: Phase IV
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Iloprost (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms VENTASWITCH
- Sponsors Bayer
- 14 Mar 2017 Status changed from active, no longer recruiting to completed.
- 25 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Feb 2017.
- 25 Nov 2016 Status changed from recruiting to active, no longer recruiting.